Sobi announces Q2 2026 results with revenue growth
Total revenue increased 29% at CER to SEK 7,842 M, driven by haematology and immunology.
See the latest news and media coverage for Sobi. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company focused on rare diseases
sobi.comLast updated
In short: Sobi reported a 29% revenue surge for Q2 2026 and completed the $1.5 billion acquisition of Arthrosi Therapeutics to expand its pipeline.
Total revenue increased 29% at CER to SEK 7,842 M, driven by haematology and immunology.
The FDA requested additional manufacturing data but no clinical safety or efficacy concerns affecting approvability.
New analyses from Phase 3 VALIANT study and its extension show sustained efficacy and safety in C3G and IC-MPGN.
Pooled Phase 3 CORE/Core2 analysis of 455 sHTG patients showed 85% reduction in acute pancreatitis and 66% triglyceride reduction at six months; EMA validation and FDA priority review ongoing.
Sobi is trading at record levels after several strong reports. But SB1's analysts see further upside for the stock and recommend buying when the analysis house initiates coverage of the company.
Sobi's HR chief, Lena Bjurner, has on Monday bought nearly 30,000 shares in the specialist pharmaceutical company for just over 7 million kronor.
Swedish Orphan Biovitrum AB (BIOVF) reports a robust 29% revenue growth, driven by key product performances and strategic pipeline advancements, despite facing competitive and regulatory...
CEO Guido Oelkers comments on the company's quarterly report and outlook.
Track Sobi and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Sobi and other trending companies.